nodes	percent_of_prediction	percent_of_DWPC	metapath
Flavoxate—PDE7A—lymphoid tissue—acquired immunodeficiency syndrome	0.0163	0.0516	CbGeAlD
Flavoxate—PDE7A—nervous system—acquired immunodeficiency syndrome	0.0125	0.0394	CbGeAlD
Flavoxate—PDE7A—central nervous system—acquired immunodeficiency syndrome	0.012	0.038	CbGeAlD
Flavoxate—PDE7B—lung—acquired immunodeficiency syndrome	0.0118	0.0372	CbGeAlD
Flavoxate—PDE7B—nervous system—acquired immunodeficiency syndrome	0.0109	0.0345	CbGeAlD
Flavoxate—PDE7B—central nervous system—acquired immunodeficiency syndrome	0.0105	0.0332	CbGeAlD
Flavoxate—PDE8B—vagina—acquired immunodeficiency syndrome	0.00991	0.0313	CbGeAlD
Flavoxate—PDE8A—blood—acquired immunodeficiency syndrome	0.00962	0.0304	CbGeAlD
Flavoxate—PDE7A—brain—acquired immunodeficiency syndrome	0.00954	0.0302	CbGeAlD
Flavoxate—PDE8B—lung—acquired immunodeficiency syndrome	0.00938	0.0296	CbGeAlD
Flavoxate—PDE8A—spinal cord—acquired immunodeficiency syndrome	0.00927	0.0293	CbGeAlD
Flavoxate—PDE8A—vagina—acquired immunodeficiency syndrome	0.00892	0.0282	CbGeAlD
Flavoxate—Eosinophilia—Nevirapine—acquired immunodeficiency syndrome	0.00877	0.0176	CcSEcCtD
Flavoxate—PDE8B—nervous system—acquired immunodeficiency syndrome	0.00868	0.0275	CbGeAlD
Flavoxate—PDE8A—lung—acquired immunodeficiency syndrome	0.00843	0.0267	CbGeAlD
Flavoxate—PDE8B—central nervous system—acquired immunodeficiency syndrome	0.00836	0.0264	CbGeAlD
Flavoxate—PDE7B—brain—acquired immunodeficiency syndrome	0.00834	0.0264	CbGeAlD
Flavoxate—PDE7B—lymph node—acquired immunodeficiency syndrome	0.00805	0.0255	CbGeAlD
Flavoxate—PDE4C—nervous system—acquired immunodeficiency syndrome	0.00804	0.0254	CbGeAlD
Flavoxate—PDE4C—central nervous system—acquired immunodeficiency syndrome	0.00774	0.0245	CbGeAlD
Flavoxate—PDE4D—lung—acquired immunodeficiency syndrome	0.00764	0.0242	CbGeAlD
Flavoxate—PDE4A—lung—acquired immunodeficiency syndrome	0.00676	0.0214	CbGeAlD
Flavoxate—PDE8B—brain—acquired immunodeficiency syndrome	0.00664	0.021	CbGeAlD
Flavoxate—PDE8B—lymph node—acquired immunodeficiency syndrome	0.00641	0.0203	CbGeAlD
Flavoxate—Eosinophilia—Delavirdine—acquired immunodeficiency syndrome	0.00619	0.0124	CcSEcCtD
Flavoxate—PDE4C—brain—acquired immunodeficiency syndrome	0.00615	0.0194	CbGeAlD
Flavoxate—Leukopenia—Didanosine—acquired immunodeficiency syndrome	0.00614	0.0123	CcSEcCtD
Flavoxate—PDE8A—brain—acquired immunodeficiency syndrome	0.00597	0.0189	CbGeAlD
Flavoxate—Skin disorder—Amprenavir—acquired immunodeficiency syndrome	0.00597	0.012	CcSEcCtD
Flavoxate—Drowsiness—Efavirenz—acquired immunodeficiency syndrome	0.00582	0.0117	CcSEcCtD
Flavoxate—PDE8A—lymph node—acquired immunodeficiency syndrome	0.00577	0.0182	CbGeAlD
Flavoxate—Dry mouth—Didanosine—acquired immunodeficiency syndrome	0.00571	0.0115	CcSEcCtD
Flavoxate—PDE4D—brain—acquired immunodeficiency syndrome	0.00541	0.0171	CbGeAlD
Flavoxate—Leukopenia—Nelfinavir—acquired immunodeficiency syndrome	0.00535	0.0107	CcSEcCtD
Flavoxate—Leukopenia—Stavudine—acquired immunodeficiency syndrome	0.00533	0.0107	CcSEcCtD
Flavoxate—Vertigo—Abacavir—acquired immunodeficiency syndrome	0.00527	0.0106	CcSEcCtD
Flavoxate—Leukopenia—Abacavir—acquired immunodeficiency syndrome	0.00525	0.0105	CcSEcCtD
Flavoxate—PDE4D—lymph node—acquired immunodeficiency syndrome	0.00523	0.0165	CbGeAlD
Flavoxate—Tension—Zidovudine—acquired immunodeficiency syndrome	0.00508	0.0102	CcSEcCtD
Flavoxate—Nervousness—Zidovudine—acquired immunodeficiency syndrome	0.00503	0.0101	CcSEcCtD
Flavoxate—Dry mouth—Stavudine—acquired immunodeficiency syndrome	0.00496	0.00995	CcSEcCtD
Flavoxate—Skin disorder—Nevirapine—acquired immunodeficiency syndrome	0.00489	0.00981	CcSEcCtD
Flavoxate—PDE4B—lymphoid tissue—acquired immunodeficiency syndrome	0.00489	0.0155	CbGeAlD
Flavoxate—PDE4A—brain—acquired immunodeficiency syndrome	0.00479	0.0151	CbGeAlD
Flavoxate—Skin disorder—Nelfinavir—acquired immunodeficiency syndrome	0.00474	0.0095	CcSEcCtD
Flavoxate—Tension—Indinavir—acquired immunodeficiency syndrome	0.00473	0.00948	CcSEcCtD
Flavoxate—Skin disorder—Stavudine—acquired immunodeficiency syndrome	0.00472	0.00947	CcSEcCtD
Flavoxate—Nervousness—Indinavir—acquired immunodeficiency syndrome	0.00468	0.00938	CcSEcCtD
Flavoxate—Skin disorder—Abacavir—acquired immunodeficiency syndrome	0.00465	0.00933	CcSEcCtD
Flavoxate—Vertigo—Zidovudine—acquired immunodeficiency syndrome	0.00465	0.00933	CcSEcCtD
Flavoxate—Leukopenia—Zidovudine—acquired immunodeficiency syndrome	0.00463	0.0093	CcSEcCtD
Flavoxate—PDE4A—lymph node—acquired immunodeficiency syndrome	0.00463	0.0146	CbGeAlD
Flavoxate—PDE4B—blood—acquired immunodeficiency syndrome	0.0046	0.0145	CbGeAlD
Flavoxate—Vision blurred—Indinavir—acquired immunodeficiency syndrome	0.00454	0.0091	CcSEcCtD
Flavoxate—Somnolence—Nevirapine—acquired immunodeficiency syndrome	0.00448	0.00898	CcSEcCtD
Flavoxate—Tension—Efavirenz—acquired immunodeficiency syndrome	0.00446	0.00895	CcSEcCtD
Flavoxate—PDE4B—bone marrow—acquired immunodeficiency syndrome	0.00445	0.0141	CbGeAlD
Flavoxate—PDE4B—spinal cord—acquired immunodeficiency syndrome	0.00443	0.014	CbGeAlD
Flavoxate—Nervousness—Efavirenz—acquired immunodeficiency syndrome	0.00442	0.00886	CcSEcCtD
Flavoxate—Somnolence—Nelfinavir—acquired immunodeficiency syndrome	0.00434	0.0087	CcSEcCtD
Flavoxate—Vertigo—Indinavir—acquired immunodeficiency syndrome	0.00433	0.00868	CcSEcCtD
Flavoxate—Somnolence—Stavudine—acquired immunodeficiency syndrome	0.00432	0.00867	CcSEcCtD
Flavoxate—Vision blurred—Efavirenz—acquired immunodeficiency syndrome	0.00429	0.0086	CcSEcCtD
Flavoxate—Tension—Delavirdine—acquired immunodeficiency syndrome	0.00427	0.00857	CcSEcCtD
Flavoxate—PDE4B—vagina—acquired immunodeficiency syndrome	0.00426	0.0135	CbGeAlD
Flavoxate—Confusional state—Zidovudine—acquired immunodeficiency syndrome	0.00426	0.00855	CcSEcCtD
Flavoxate—Palpitations—Indinavir—acquired immunodeficiency syndrome	0.00426	0.00854	CcSEcCtD
Flavoxate—Nervousness—Delavirdine—acquired immunodeficiency syndrome	0.00423	0.00848	CcSEcCtD
Flavoxate—Feeling abnormal—Nevirapine—acquired immunodeficiency syndrome	0.00415	0.00832	CcSEcCtD
Flavoxate—Skin disorder—Zidovudine—acquired immunodeficiency syndrome	0.0041	0.00823	CcSEcCtD
Flavoxate—Vision blurred—Delavirdine—acquired immunodeficiency syndrome	0.0041	0.00823	CcSEcCtD
Flavoxate—Vertigo—Efavirenz—acquired immunodeficiency syndrome	0.00409	0.0082	CcSEcCtD
Flavoxate—PDE4B—lung—acquired immunodeficiency syndrome	0.00403	0.0128	CbGeAlD
Flavoxate—Palpitations—Efavirenz—acquired immunodeficiency syndrome	0.00402	0.00806	CcSEcCtD
Flavoxate—Feeling abnormal—Nelfinavir—acquired immunodeficiency syndrome	0.00402	0.00806	CcSEcCtD
Flavoxate—Dry mouth—Indinavir—acquired immunodeficiency syndrome	0.00401	0.00804	CcSEcCtD
Flavoxate—Urticaria—Nevirapine—acquired immunodeficiency syndrome	0.004	0.00802	CcSEcCtD
Flavoxate—Tension—Ritonavir—acquired immunodeficiency syndrome	0.00395	0.00792	CcSEcCtD
Flavoxate—Feeling abnormal—Abacavir—acquired immunodeficiency syndrome	0.00395	0.00792	CcSEcCtD
Flavoxate—Vertigo—Delavirdine—acquired immunodeficiency syndrome	0.00391	0.00784	CcSEcCtD
Flavoxate—Nervousness—Ritonavir—acquired immunodeficiency syndrome	0.00391	0.00784	CcSEcCtD
Flavoxate—Vomiting—Amprenavir—acquired immunodeficiency syndrome	0.00391	0.00783	CcSEcCtD
Flavoxate—Leukopenia—Delavirdine—acquired immunodeficiency syndrome	0.0039	0.00782	CcSEcCtD
Flavoxate—Urticaria—Nelfinavir—acquired immunodeficiency syndrome	0.00387	0.00777	CcSEcCtD
Flavoxate—Urticaria—Stavudine—acquired immunodeficiency syndrome	0.00386	0.00775	CcSEcCtD
Flavoxate—Headache—Amprenavir—acquired immunodeficiency syndrome	0.00385	0.00772	CcSEcCtD
Flavoxate—Palpitations—Delavirdine—acquired immunodeficiency syndrome	0.00385	0.00772	CcSEcCtD
Flavoxate—Skin disorder—Indinavir—acquired immunodeficiency syndrome	0.00382	0.00766	CcSEcCtD
Flavoxate—Urticaria—Abacavir—acquired immunodeficiency syndrome	0.0038	0.00763	CcSEcCtD
Flavoxate—Vision blurred—Ritonavir—acquired immunodeficiency syndrome	0.00379	0.00761	CcSEcCtD
Flavoxate—Dry mouth—Efavirenz—acquired immunodeficiency syndrome	0.00379	0.0076	CcSEcCtD
Flavoxate—Somnolence—Zidovudine—acquired immunodeficiency syndrome	0.00376	0.00754	CcSEcCtD
Flavoxate—Confusional state—Efavirenz—acquired immunodeficiency syndrome	0.00374	0.00751	CcSEcCtD
Flavoxate—PDE4B—nervous system—acquired immunodeficiency syndrome	0.00373	0.0118	CbGeAlD
Flavoxate—CHRM2—nervous system—acquired immunodeficiency syndrome	0.00371	0.0117	CbGeAlD
Flavoxate—Nausea—Amprenavir—acquired immunodeficiency syndrome	0.00365	0.00732	CcSEcCtD
Flavoxate—CHRM1—lung—acquired immunodeficiency syndrome	0.00365	0.0115	CbGeAlD
Flavoxate—Tension—Lamivudine—acquired immunodeficiency syndrome	0.00363	0.00728	CcSEcCtD
Flavoxate—Dry mouth—Delavirdine—acquired immunodeficiency syndrome	0.00362	0.00727	CcSEcCtD
Flavoxate—Tachycardia—Efavirenz—acquired immunodeficiency syndrome	0.00362	0.00727	CcSEcCtD
Flavoxate—Vertigo—Ritonavir—acquired immunodeficiency syndrome	0.00362	0.00725	CcSEcCtD
Flavoxate—Skin disorder—Efavirenz—acquired immunodeficiency syndrome	0.00361	0.00723	CcSEcCtD
Flavoxate—Leukopenia—Ritonavir—acquired immunodeficiency syndrome	0.0036	0.00723	CcSEcCtD
Flavoxate—PDE4B—central nervous system—acquired immunodeficiency syndrome	0.0036	0.0114	CbGeAlD
Flavoxate—Nervousness—Lamivudine—acquired immunodeficiency syndrome	0.00359	0.0072	CcSEcCtD
Flavoxate—Confusional state—Delavirdine—acquired immunodeficiency syndrome	0.00358	0.00719	CcSEcCtD
Flavoxate—CHRM2—central nervous system—acquired immunodeficiency syndrome	0.00357	0.0113	CbGeAlD
Flavoxate—Vomiting—Didanosine—acquired immunodeficiency syndrome	0.00356	0.00714	CcSEcCtD
Flavoxate—Palpitations—Ritonavir—acquired immunodeficiency syndrome	0.00356	0.00714	CcSEcCtD
Flavoxate—Headache—Didanosine—acquired immunodeficiency syndrome	0.00351	0.00704	CcSEcCtD
Flavoxate—Somnolence—Indinavir—acquired immunodeficiency syndrome	0.00349	0.00701	CcSEcCtD
Flavoxate—Feeling abnormal—Zidovudine—acquired immunodeficiency syndrome	0.00348	0.00698	CcSEcCtD
Flavoxate—Vertigo—Saquinavir—acquired immunodeficiency syndrome	0.00348	0.00698	CcSEcCtD
Flavoxate—Leukopenia—Saquinavir—acquired immunodeficiency syndrome	0.00347	0.00696	CcSEcCtD
Flavoxate—Tachycardia—Delavirdine—acquired immunodeficiency syndrome	0.00347	0.00695	CcSEcCtD
Flavoxate—Skin disorder—Delavirdine—acquired immunodeficiency syndrome	0.00345	0.00692	CcSEcCtD
Flavoxate—CHRM1—nervous system—acquired immunodeficiency syndrome	0.00338	0.0107	CbGeAlD
Flavoxate—Urticaria—Zidovudine—acquired immunodeficiency syndrome	0.00336	0.00673	CcSEcCtD
Flavoxate—Dry mouth—Ritonavir—acquired immunodeficiency syndrome	0.00335	0.00672	CcSEcCtD
Flavoxate—Nausea—Didanosine—acquired immunodeficiency syndrome	0.00333	0.00667	CcSEcCtD
Flavoxate—Vertigo—Lamivudine—acquired immunodeficiency syndrome	0.00332	0.00666	CcSEcCtD
Flavoxate—Confusional state—Ritonavir—acquired immunodeficiency syndrome	0.00331	0.00664	CcSEcCtD
Flavoxate—Leukopenia—Lamivudine—acquired immunodeficiency syndrome	0.00331	0.00664	CcSEcCtD
Flavoxate—Somnolence—Efavirenz—acquired immunodeficiency syndrome	0.0033	0.00662	CcSEcCtD
Flavoxate—CHRM1—central nervous system—acquired immunodeficiency syndrome	0.00325	0.0103	CbGeAlD
Flavoxate—Feeling abnormal—Indinavir—acquired immunodeficiency syndrome	0.00324	0.0065	CcSEcCtD
Flavoxate—Dry mouth—Saquinavir—acquired immunodeficiency syndrome	0.00323	0.00647	CcSEcCtD
Flavoxate—Tachycardia—Ritonavir—acquired immunodeficiency syndrome	0.00321	0.00643	CcSEcCtD
Flavoxate—Vomiting—Nevirapine—acquired immunodeficiency syndrome	0.0032	0.00642	CcSEcCtD
Flavoxate—Skin disorder—Ritonavir—acquired immunodeficiency syndrome	0.00319	0.0064	CcSEcCtD
Flavoxate—Confusional state—Saquinavir—acquired immunodeficiency syndrome	0.00319	0.0064	CcSEcCtD
Flavoxate—Somnolence—Delavirdine—acquired immunodeficiency syndrome	0.00316	0.00634	CcSEcCtD
Flavoxate—Headache—Nevirapine—acquired immunodeficiency syndrome	0.00315	0.00633	CcSEcCtD
Flavoxate—Urticaria—Indinavir—acquired immunodeficiency syndrome	0.00312	0.00626	CcSEcCtD
Flavoxate—Vomiting—Nelfinavir—acquired immunodeficiency syndrome	0.0031	0.00622	CcSEcCtD
Flavoxate—Vomiting—Stavudine—acquired immunodeficiency syndrome	0.00309	0.0062	CcSEcCtD
Flavoxate—Dry mouth—Lamivudine—acquired immunodeficiency syndrome	0.00308	0.00617	CcSEcCtD
Flavoxate—Skin disorder—Saquinavir—acquired immunodeficiency syndrome	0.00307	0.00616	CcSEcCtD
Flavoxate—Feeling abnormal—Efavirenz—acquired immunodeficiency syndrome	0.00306	0.00614	CcSEcCtD
Flavoxate—Headache—Nelfinavir—acquired immunodeficiency syndrome	0.00306	0.00613	CcSEcCtD
Flavoxate—Headache—Stavudine—acquired immunodeficiency syndrome	0.00305	0.00611	CcSEcCtD
Flavoxate—Vomiting—Abacavir—acquired immunodeficiency syndrome	0.00305	0.00611	CcSEcCtD
Flavoxate—Confusional state—Lamivudine—acquired immunodeficiency syndrome	0.00304	0.0061	CcSEcCtD
Flavoxate—Headache—Abacavir—acquired immunodeficiency syndrome	0.003	0.00602	CcSEcCtD
Flavoxate—Nausea—Nevirapine—acquired immunodeficiency syndrome	0.00299	0.006	CcSEcCtD
Flavoxate—Urticaria—Efavirenz—acquired immunodeficiency syndrome	0.00295	0.00592	CcSEcCtD
Flavoxate—Skin disorder—Lamivudine—acquired immunodeficiency syndrome	0.00293	0.00588	CcSEcCtD
Flavoxate—Feeling abnormal—Delavirdine—acquired immunodeficiency syndrome	0.00293	0.00587	CcSEcCtD
Flavoxate—Somnolence—Ritonavir—acquired immunodeficiency syndrome	0.00292	0.00586	CcSEcCtD
Flavoxate—Nausea—Nelfinavir—acquired immunodeficiency syndrome	0.0029	0.00581	CcSEcCtD
Flavoxate—Nausea—Stavudine—acquired immunodeficiency syndrome	0.00289	0.00579	CcSEcCtD
Flavoxate—PDE4B—brain—acquired immunodeficiency syndrome	0.00285	0.00903	CbGeAlD
Flavoxate—Nausea—Abacavir—acquired immunodeficiency syndrome	0.00284	0.00571	CcSEcCtD
Flavoxate—CHRM2—brain—acquired immunodeficiency syndrome	0.00284	0.00896	CbGeAlD
Flavoxate—Urticaria—Delavirdine—acquired immunodeficiency syndrome	0.00282	0.00566	CcSEcCtD
Flavoxate—Somnolence—Saquinavir—acquired immunodeficiency syndrome	0.00281	0.00564	CcSEcCtD
Flavoxate—PDE4B—lymph node—acquired immunodeficiency syndrome	0.00276	0.00872	CbGeAlD
Flavoxate—Feeling abnormal—Ritonavir—acquired immunodeficiency syndrome	0.00271	0.00543	CcSEcCtD
Flavoxate—Vomiting—Zidovudine—acquired immunodeficiency syndrome	0.00269	0.00539	CcSEcCtD
Flavoxate—Somnolence—Lamivudine—acquired immunodeficiency syndrome	0.00268	0.00538	CcSEcCtD
Flavoxate—Headache—Zidovudine—acquired immunodeficiency syndrome	0.00265	0.00531	CcSEcCtD
Flavoxate—Urticaria—Ritonavir—acquired immunodeficiency syndrome	0.00261	0.00524	CcSEcCtD
Flavoxate—Feeling abnormal—Saquinavir—acquired immunodeficiency syndrome	0.00261	0.00523	CcSEcCtD
Flavoxate—CHRM1—brain—acquired immunodeficiency syndrome	0.00258	0.00816	CbGeAlD
Flavoxate—Urticaria—Saquinavir—acquired immunodeficiency syndrome	0.00251	0.00504	CcSEcCtD
Flavoxate—Nausea—Zidovudine—acquired immunodeficiency syndrome	0.00251	0.00503	CcSEcCtD
Flavoxate—Vomiting—Indinavir—acquired immunodeficiency syndrome	0.0025	0.00501	CcSEcCtD
Flavoxate—Feeling abnormal—Lamivudine—acquired immunodeficiency syndrome	0.00249	0.00499	CcSEcCtD
Flavoxate—Headache—Indinavir—acquired immunodeficiency syndrome	0.00246	0.00494	CcSEcCtD
Flavoxate—Urticaria—Lamivudine—acquired immunodeficiency syndrome	0.0024	0.00481	CcSEcCtD
Flavoxate—Vomiting—Efavirenz—acquired immunodeficiency syndrome	0.00236	0.00474	CcSEcCtD
Flavoxate—Nausea—Indinavir—acquired immunodeficiency syndrome	0.00233	0.00468	CcSEcCtD
Flavoxate—Headache—Efavirenz—acquired immunodeficiency syndrome	0.00233	0.00467	CcSEcCtD
Flavoxate—Vomiting—Delavirdine—acquired immunodeficiency syndrome	0.00226	0.00453	CcSEcCtD
Flavoxate—Headache—Delavirdine—acquired immunodeficiency syndrome	0.00223	0.00446	CcSEcCtD
Flavoxate—Nausea—Efavirenz—acquired immunodeficiency syndrome	0.00221	0.00442	CcSEcCtD
Flavoxate—Nausea—Delavirdine—acquired immunodeficiency syndrome	0.00211	0.00423	CcSEcCtD
Flavoxate—Vomiting—Ritonavir—acquired immunodeficiency syndrome	0.00209	0.00419	CcSEcCtD
Flavoxate—Headache—Ritonavir—acquired immunodeficiency syndrome	0.00206	0.00413	CcSEcCtD
Flavoxate—Vomiting—Saquinavir—acquired immunodeficiency syndrome	0.00201	0.00403	CcSEcCtD
Flavoxate—Headache—Saquinavir—acquired immunodeficiency syndrome	0.00198	0.00397	CcSEcCtD
Flavoxate—Nausea—Ritonavir—acquired immunodeficiency syndrome	0.00195	0.00391	CcSEcCtD
Flavoxate—Vomiting—Lamivudine—acquired immunodeficiency syndrome	0.00192	0.00385	CcSEcCtD
Flavoxate—Headache—Lamivudine—acquired immunodeficiency syndrome	0.00189	0.00379	CcSEcCtD
Flavoxate—Nausea—Saquinavir—acquired immunodeficiency syndrome	0.00188	0.00377	CcSEcCtD
Flavoxate—Nausea—Lamivudine—acquired immunodeficiency syndrome	0.00179	0.00359	CcSEcCtD
Flavoxate—PDE7A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000491	0.00265	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.00049	0.00265	CbGpPWpGaD
Flavoxate—PDE7A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000484	0.00262	CbGpPWpGaD
Flavoxate—CHRM2—G alpha (i) signalling events—CXCR4—acquired immunodeficiency syndrome	0.000482	0.0026	CbGpPWpGaD
Flavoxate—CHRM2—G alpha (i) signalling events—CXCL12—acquired immunodeficiency syndrome	0.000482	0.0026	CbGpPWpGaD
Flavoxate—CHRM1—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000482	0.0026	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000478	0.00258	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.000477	0.00257	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Class A Rhodopsin-like—CCR2—acquired immunodeficiency syndrome	0.000476	0.00257	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000472	0.00255	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CCL3L1—acquired immunodeficiency syndrome	0.00047	0.00254	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.00047	0.00254	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000468	0.00253	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000461	0.00249	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000461	0.00249	CbGpPWpGaD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000457	0.00247	CbGpPWpGaD
Flavoxate—CHRM1—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000453	0.00245	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000451	0.00244	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000451	0.00244	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL3—acquired immunodeficiency syndrome	0.000451	0.00243	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000449	0.00243	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000449	0.00243	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000449	0.00242	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Class A Rhodopsin-like—CXCR4—acquired immunodeficiency syndrome	0.000447	0.00242	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000447	0.00241	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000444	0.0024	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000442	0.00238	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000442	0.00238	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000429	0.00232	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000429	0.00232	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000427	0.0023	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.00042	0.00227	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.00042	0.00227	CbGpPWpGaD
Flavoxate—PDE4D—Myometrial Relaxation and Contraction Pathways—IL6—acquired immunodeficiency syndrome	0.000419	0.00226	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000418	0.00226	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000418	0.00226	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000415	0.00224	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000414	0.00223	CbGpPWpGaD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000413	0.00223	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000408	0.0022	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR2—acquired immunodeficiency syndrome	0.000408	0.0022	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000406	0.00219	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000401	0.00217	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000401	0.00217	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000397	0.00214	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000397	0.00214	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000389	0.0021	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000389	0.0021	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000388	0.0021	CbGpPWpGaD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000388	0.0021	CbGpPWpGaD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000388	0.0021	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000386	0.00208	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000383	0.00207	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000383	0.00207	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCR4—acquired immunodeficiency syndrome	0.000383	0.00207	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—CXCL12—acquired immunodeficiency syndrome	0.000383	0.00207	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000382	0.00206	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000382	0.00206	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.00038	0.00205	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000378	0.00204	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000378	0.00204	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000376	0.00203	CbGpPWpGaD
Flavoxate—PDE8B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000372	0.00201	CbGpPWpGaD
Flavoxate—PDE8A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000372	0.00201	CbGpPWpGaD
Flavoxate—PDE4B—Myometrial Relaxation and Contraction Pathways—IL6—acquired immunodeficiency syndrome	0.000369	0.00199	CbGpPWpGaD
Flavoxate—CHRM2—G alpha (i) signalling events—CCL5—acquired immunodeficiency syndrome	0.000367	0.00198	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000359	0.00194	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000353	0.00191	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000353	0.00191	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.00035	0.00189	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000348	0.00188	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000348	0.00188	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000345	0.00187	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000345	0.00187	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000345	0.00186	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—CCL3—acquired immunodeficiency syndrome	0.000343	0.00185	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000342	0.00185	CbGpPWpGaD
Flavoxate—PDE8A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000338	0.00182	CbGpPWpGaD
Flavoxate—PDE8B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000338	0.00182	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000337	0.00182	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000336	0.00181	CbGpPWpGaD
Flavoxate—PDE7B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000332	0.00179	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000331	0.00179	CbGpPWpGaD
Flavoxate—CHRM2—G alpha (i) signalling events—CCR5—acquired immunodeficiency syndrome	0.00033	0.00178	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.00032	0.00173	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.00032	0.00173	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000318	0.00172	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000316	0.00171	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000315	0.0017	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.000314	0.0017	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000313	0.00169	CbGpPWpGaD
Flavoxate—CHRM1—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000311	0.00168	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—CCR2—acquired immunodeficiency syndrome	0.00031	0.00168	CbGpPWpGaD
Flavoxate—PDE7A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000308	0.00166	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000308	0.00166	CbGpPWpGaD
Flavoxate—CHRM2—GPCRs, Class A Rhodopsin-like—CCR5—acquired immunodeficiency syndrome	0.000307	0.00166	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000305	0.00165	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000303	0.00163	CbGpPWpGaD
Flavoxate—PDE7B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000301	0.00163	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000301	0.00162	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000296	0.0016	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000296	0.0016	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000296	0.0016	CbGpPWpGaD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000295	0.00159	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—CXCR4—acquired immunodeficiency syndrome	0.000292	0.00158	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—CXCL12—acquired immunodeficiency syndrome	0.000292	0.00158	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCL5—acquired immunodeficiency syndrome	0.000291	0.00157	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000291	0.00157	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.00029	0.00157	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000289	0.00156	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000289	0.00156	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000288	0.00156	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000286	0.00155	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000286	0.00154	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—ACKR1—acquired immunodeficiency syndrome	0.000285	0.00154	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000282	0.00152	CbGpPWpGaD
Flavoxate—PDE7A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.00028	0.00151	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000279	0.0015	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCL3L1—acquired immunodeficiency syndrome	0.000278	0.0015	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000275	0.00148	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000272	0.00147	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000272	0.00147	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000269	0.00145	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000267	0.00144	CbGpPWpGaD
Flavoxate—CHRM1—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000266	0.00144	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000265	0.00143	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000265	0.00143	CbGpPWpGaD
Flavoxate—CHRM2—Class A/1 (Rhodopsin-like receptors)—CCR5—acquired immunodeficiency syndrome	0.000263	0.00142	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000262	0.00141	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000261	0.00141	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CCL4—acquired immunodeficiency syndrome	0.000258	0.00139	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000252	0.00136	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000245	0.00133	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000242	0.00131	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.00024	0.0013	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000237	0.00128	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000237	0.00128	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000225	0.00122	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000225	0.00122	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000225	0.00121	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—CCL5—acquired immunodeficiency syndrome	0.000222	0.0012	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	0.000222	0.0012	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	0.000209	0.00113	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	0.000209	0.00113	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000207	0.00112	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000204	0.0011	CbGpPWpGaD
Flavoxate—CHRM1—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.000203	0.00109	CbGpPWpGaD
Flavoxate—PDE4C—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000201	0.00108	CbGpPWpGaD
Flavoxate—CHRM2—GPCR ligand binding—CCR5—acquired immunodeficiency syndrome	0.0002	0.00108	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.0002	0.00108	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.0002	0.00108	CbGpPWpGaD
Flavoxate—PDE8B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000199	0.00107	CbGpPWpGaD
Flavoxate—PDE8A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000199	0.00107	CbGpPWpGaD
Flavoxate—CHRM2—SIDS Susceptibility Pathways—TNF—acquired immunodeficiency syndrome	0.000193	0.00104	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000187	0.00101	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000182	0.000985	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.00018	0.000973	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000178	0.000963	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000178	0.000961	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000178	0.000959	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000178	0.000959	CbGpPWpGaD
Flavoxate—PDE7B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000177	0.000956	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CCL3—acquired immunodeficiency syndrome	0.000176	0.000951	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—CCR2—acquired immunodeficiency syndrome	0.000175	0.000947	CbGpPWpGaD
Flavoxate—PDE4D—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000175	0.000944	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000172	0.000926	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000171	0.000921	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000171	0.000921	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000169	0.000913	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCNT1—acquired immunodeficiency syndrome	0.000168	0.000909	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—ACKR1—acquired immunodeficiency syndrome	0.000168	0.000909	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000167	0.000902	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000167	0.000902	CbGpPWpGaD
Flavoxate—PDE4A—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000166	0.000899	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000165	0.000893	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—CXCL12—acquired immunodeficiency syndrome	0.000165	0.000891	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—CXCR4—acquired immunodeficiency syndrome	0.000165	0.000891	CbGpPWpGaD
Flavoxate—PDE7A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000165	0.000889	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000162	0.000877	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000161	0.000871	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CCR2—acquired immunodeficiency syndrome	0.000159	0.00086	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000159	0.000858	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	0.000159	0.000857	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	0.000156	0.000844	CbGpPWpGaD
Flavoxate—CHRM2—SIDS Susceptibility Pathways—IL6—acquired immunodeficiency syndrome	0.000156	0.000841	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000155	0.000835	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000154	0.000833	CbGpPWpGaD
Flavoxate—PDE4B—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	0.000154	0.000832	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCL4—acquired immunodeficiency syndrome	0.000152	0.000822	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.000152	0.000819	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.000152	0.000819	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.000151	0.000816	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CXCR4—acquired immunodeficiency syndrome	0.00015	0.000809	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CXCL12—acquired immunodeficiency syndrome	0.00015	0.000809	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	0.000143	0.000772	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	0.00014	0.000755	CbGpPWpGaD
Flavoxate—CHRM1—Circadian rythm related genes—IL6—acquired immunodeficiency syndrome	0.000129	0.000695	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000127	0.000686	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—CCL5—acquired immunodeficiency syndrome	0.000125	0.000677	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000125	0.000676	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—CSF2—acquired immunodeficiency syndrome	0.000124	0.000667	CbGpPWpGaD
Flavoxate—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—acquired immunodeficiency syndrome	0.000122	0.000659	CbGpPWpGaD
Flavoxate—PDE8B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	0.000117	0.000633	CbGpPWpGaD
Flavoxate—PDE8A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	0.000117	0.000633	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000115	0.000623	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000114	0.000618	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CCL5—acquired immunodeficiency syndrome	0.000114	0.000615	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000114	0.000614	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—CCR5—acquired immunodeficiency syndrome	0.000113	0.00061	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CSF2—acquired immunodeficiency syndrome	0.000112	0.000606	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—IL2—acquired immunodeficiency syndrome	0.000108	0.000582	CbGpPWpGaD
Flavoxate—PDE4C—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	0.000107	0.000579	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000105	0.000569	CbGpPWpGaD
Flavoxate—PDE7B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	0.000105	0.000565	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCL3—acquired immunodeficiency syndrome	0.000104	0.000562	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000104	0.000561	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—CCR5—acquired immunodeficiency syndrome	0.000103	0.000554	CbGpPWpGaD
Flavoxate—PDE7A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	9.72e-05	0.000525	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.53e-05	0.000515	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCR2—acquired immunodeficiency syndrome	9.41e-05	0.000508	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—IL2—acquired immunodeficiency syndrome	9.38e-05	0.000507	CbGpPWpGaD
Flavoxate—PDE4D—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	9.33e-05	0.000504	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.96e-05	0.000484	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.96e-05	0.000484	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.93e-05	0.000482	CbGpPWpGaD
Flavoxate—PDE4A—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.88e-05	0.00048	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CXCR4—acquired immunodeficiency syndrome	8.85e-05	0.000478	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CXCL12—acquired immunodeficiency syndrome	8.85e-05	0.000478	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—IL2—acquired immunodeficiency syndrome	8.26e-05	0.000446	CbGpPWpGaD
Flavoxate—PDE4B—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	8.22e-05	0.000444	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.82e-05	0.000368	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCL5—acquired immunodeficiency syndrome	6.73e-05	0.000363	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.71e-05	0.000363	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CSF2—acquired immunodeficiency syndrome	6.63e-05	0.000358	CbGpPWpGaD
Flavoxate—CHRM1—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.61e-05	0.000357	CbGpPWpGaD
Flavoxate—CHRM2—GPCR downstream signaling—IL2—acquired immunodeficiency syndrome	6.53e-05	0.000353	CbGpPWpGaD
Flavoxate—PDE4C—Signaling Pathways—IL6—acquired immunodeficiency syndrome	6.33e-05	0.000342	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.14e-05	0.000332	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—CCR5—acquired immunodeficiency syndrome	6.06e-05	0.000327	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	6.01e-05	0.000324	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—IL2—acquired immunodeficiency syndrome	5.93e-05	0.00032	CbGpPWpGaD
Flavoxate—PDE4D—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.51e-05	0.000298	CbGpPWpGaD
Flavoxate—PDE4A—Signaling Pathways—IL6—acquired immunodeficiency syndrome	5.25e-05	0.000283	CbGpPWpGaD
Flavoxate—PDE4B—Signaling Pathways—IL6—acquired immunodeficiency syndrome	4.86e-05	0.000262	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.55e-05	0.000192	CbGpPWpGaD
Flavoxate—CHRM1—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.53e-05	0.000191	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IL2—acquired immunodeficiency syndrome	3.5e-05	0.000189	CbGpPWpGaD
Flavoxate—CHRM2—Signaling by GPCR—IL6—acquired immunodeficiency syndrome	3.49e-05	0.000188	CbGpPWpGaD
Flavoxate—CHRM1—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.09e-05	0.000113	CbGpPWpGaD
Flavoxate—CHRM2—Signaling Pathways—IL6—acquired immunodeficiency syndrome	2.06e-05	0.000111	CbGpPWpGaD
